Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin Huls

Showing results (161-170 of 162) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 162 results.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Pageof 17

Showing results (161-170 of 162) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 162 results.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Pageof 17